Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT04432857 is registered in ClinicalTrials.gov with Adlai Nortye Biopharma Co., Ltd. as lead sponsor.

NCT NCT04432857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 20, 2020
Completion date
January 30, 2025
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, microsatellite stable (mss) colorectal cancer (crc), nsclc, squamous or non-squamous, triple-negative breast cancer, urothelial carcinoma of the bladder